BioGaia has extended its collaboration with the Swiss
biopharmaceutical company Ferring Pharmaceuticals giving Ferring
exclusive rights to sell BioGaia's Probiotic Drops in Ireland and
exclusive rights to sell BioGaia's Probiotic Drops and Tablets in
Bahrain, Yemen, Qatar, Oman, Kuwait and United Arab Emirates."We are very happy to again expand the contract with Ferring in to
these interesting markets. Ferring is taking the BioGaia brand to
markets we have not been before and it is yet another step in our
effort to build a global probiotic brand ", says Peter Rothschild,
President, BioGaia AB."Our collaboration with BioGaia is going very well. BioGaia's
Probiotic therapeutic products have been very well received by the
medical profession and patients in the countries where we have
already launched and we are very happy to be able to make it
available to patients in the Gulf States and Ireland " says Michel
Pettigrew, COO at Ferring.
Ferring Pharmaceuticals is a Swiss-based research driven, specialty
biopharmaceutical group active in global markets. The company
identifies, develops and markets innovative products in the areas of
endocrinology, gastroenterology, gynaecology, fertility and urology.
In recent years Ferring has expanded beyond its traditional European
base and has operations in over 40 countries. To learn more about
Ferring or its products please visit www.ferring.com.
Latest press releases from BioGaia:
2008-11-13 BioGaia expands collaboration in Ukraine and Kazakhstan
2008-11-10 Product from BioGaia counteracts bleeding gums by
interacting with the immune system
2008-10-23 BioGaia AB Interim report 1 January - 30 September 2008
For additional information contact: Peter Rothschild, Managing
Director, telephone: +46 8 - 555 293 00,
Jan Annwall, Deputy Managing Director telephone: +46 8 - 555 293 00
Helen Gallagher, Ferring Pharmaceuticals, Tel: +41 58 301 00 51, Fax:
+41 58 301 0039
e-mail: helen.gallagher@ferring.com
BioGaia is a biotechnology company that develops, markets and sells
probiotic products with documented health benefits. The products are
primarily based on the lactic acid bacterium Lactobacillus reuteri
(Reuteri), which has probiotic, health-enhancing effects. The class B
share of the Parent Company BioGaia AB is quoted on the Small Cap
list of the Nordic Stock Exchange in Stockholm.
www.biogaia.com
